Special contact lenses can diagnose glaucoma
Glaucoma affects around 70 million people worldwide and can cause irreversible loss of vision if not treated — but around half of those living with the condition are not aware of it. Indeed, many cases of glaucoma are only picked up during routine eye tests, by which time lasting damage may already have been caused. But this could change in future as researchers have developed a contact lens that can detect changes in eye pressure that signal possible glaucoma.
Glaucoma occurs when the optic nerve, which connects the eye to the brain, becomes damaged, usually by a build-up of fluid in the front part of the eye which increases pressure inside the eye — known as intra-ocular pressure (IOP). The new contact lenses contain micro-sensors that monitor changes in IOP over a period of several hours, sending the data collected wirelessly so it can be analysed by an ophthalmologist and a diagnosis given.
“IOP can vary greatly over a 24-hour period, so it is important to monitor the patient either at intervals or ideally continuously for a whole day to get the best insight into the health of their eyes,” said Professor Hamdi Torun of Northumbria University in the UK.
“Traditional methods for measuring IOP involve initially going to a clinic for a single measurement in a day, the result of which can be misleading due to the natural variation of IOP.
“If a variation is detected, further investigation is then needed, which requires hospitalisation for a whole day, during which repeated measurements are taken using a technique called Goldmann applanation tonometry, which involves numbing the eye with drops and then using a small cone to touch the cornea to measure the pressure.
“However, studies have shown that waking patients up at night to carry out measurements can make the results less accurate, in addition to obvious discomfort to the patients and the economic cost to the healthcare system.
“The benefit of the contact lenses we have developed is that once placed in the eye, the patient can then go about their day as normal while their IOP measurements are recorded and sent to a doctor for analysis once the 24-hour period of testing is complete,” Torun said. The work was a collaboration between Northumbria University and Boğaziçi University, Türkiye.
While this is not the first time contact lenses have been developed to measure IOP, previous products have used an electrically active silicon chip, which results in a thicker, less comfortable, less flexible lens which can restrict vision, making it more difficult to carry out daily activities. The new contact lenses use an electrically passive sensor embedded in a disposable soft contact lens and a wearable electronic readout system to collect, store and process the data — making the lens more comfortable and allowing the patient to go about their day as normal.
The new system has so far been tested in a pilot study of six healthy volunteers, who were asked to drink 1.5 litres of water and lie flat to intentionally increase their IOP levels. With their successful results published in the journal Contact Lens and Anterior Eye, the researchers now plan to carry out a further study with a larger group of participants, which will take place over the next year. The lenses will then be made commercially available through spin-off company GlakoLens.
As well as diagnosing glaucoma, there is also potential for the lenses to be used to detect other health conditions by measuring glucose, lactic acid and other molecules present in eyes. According to Torun, “We believe this technology has huge potential and could not only save the sight of patients in the early stages of glaucoma but also provide early diagnosis of other diseases in future.”
Children's heart implant expands when activated by light
Researchers have designed a shunt that expands when activated by light, which could reduce the...
Elite controllers could hold the key to treating HIV
Equipped with MGI's advanced sequencing tools and technologies, South African researchers are...
Improving autoimmune conditions in Down syndrome patients
A first-in-kind clinical trial has tested the safety and efficacy of a JAK inhibitor in...